Next Phase Newsletter

A healthcare investment firm with offices in the USA actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes.

The firm typically makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm with offices in the USA is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America.

The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest.

The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm in Western Europe has the capability to leverage the experience resources from a dedicated life sciences consulting firm (of the same name but separate legal entities) with multiple offices throughout the globe. With the capability to leverage the experienced resources from the consulting firm, the firm is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.

The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.

The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital founded in 2006 and based in USA, makes equity investments of up to $4 million into companies over the lifetime of the investment in both the seed and venture stage. The firm is most interested in companies located in California especially for seed stage deals, but will consider investments throughout the United States. The firm is actively seeking new investment opportunities.

The firm is looking for companies in the Medical Device space. The firm is looking for companies in all stages of development and across areas of medicine including cardiovascular and general surgery, orthopedic surgery, cardiology, radiology, oncology, obesity, gynecology, sleep disorders and more including orphan indications.

The firm is looking for companies with experienced management teams though the management team need not be complete. The firm is able to provide assistance in filling gaps in these teams through the firm’s connections in the industry. The firm looks to take a board seat into companies following investment

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is the corporate venture arm of a Japan-based global pharmaceutical company. The firm seeks to make strategic investments into early-stage companies that are aligned with the parent company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the parent company’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent organization.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a global HealthTech and Life Sciences investment fund based in the Middle East. With approximately $1.3 billion AUM, the firm partners with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with their portfolio companies, they work tirelessly to advance solutions that will help people live healthier, better lives. Multidisciplinary by nature, the team has been purpose-built to invest in the HealthTech and life sciences arena. The multidisciplinary team is composed of scientists, physicians, engineers, entrepreneurs, and investors with global experience who are dedicated to science, medicine, and technology. When they partner with a company, they bring the power of their platform to assist management teams and support them as they execute their plans. Through their early stage fund, they invest in companies pursuing disruptive, cutting-edge technologies as early as sponsored research at top academic and clinical institutions to venture formation through seed investments and A rounds. The fund’s initial investments are typically in the range of $0.1-5 million, depending on the stage of the company, with significant amounts reserved for follow on investments in well performing portfolio companies. The growth fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds, or in pivotal clinical trials. The growth fund’s initial investments are typically in the range of $10-30 million.

The firm invests broadly in healthtech and life sciences, including therapeutics, medical devices, diagnostics, and digital health companies that address areas of unmet need. The firm has a strong interest in personalized, preventive, and precision medicine technologies and those that could improve access to care, quality of care, and cost of care.

The growth fund pursues investments in companies that are advancing the multi-omics revolution, personalizing medicine, expanding next-generation gene/cell therapy, engineering biology, and digitizing diagnostics. In Biotech and Medtech they get excited by companies that have achieved initial clinical proof of concept and can reach a significant efficacy readout over the next two years. In life science tools and diagnostics, they look for companies that have developed breakthrough instruments that are approaching or in the midst of beta testing and will begin commercialization shortly. In digital health they seek out companies that have achieved initial repeat revenues and are looking to scale commercially. At the early stage fund, they don’t define themselves by vertical, need, or even geographical boundaries but searching for transformational solutions to healthier lives and accelerated paths for value creation and building world-leading companies.

The firm seeks out great management teams that are smart problems solvers. The firm likes great technologies, but what really moves them is evidence of a highly compelling product-market fit. Market size is a consideration, but the firm cares much more about the ability to gain market access. More than momentary valuation, the firm focuses on the value that can be created by answering an unmet medical need.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a private life science investment firm with a presence in London, New York, Boston, Toronto and San Francisco. The firm looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $.5-$3million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immune-oncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm is a hands-on investor which contributes substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.